Publications by authors named "Yanru Fei"
Article Synopsis
- Coxsackievirus B (CVB) is linked to serious illnesses like myocarditis, meningitis, and pancreatitis, with no effective antiviral treatments available due to incomplete understanding of its pathogenesis.
- The study identifies that the 3D protein of CVB3 undergoes K48-linked polyubiquitination, leading to its degradation by the proteasome, with E3 ligase TRIM56 playing a crucial role in this process.
- Findings suggest that TRIM56 acts as a cellular defense mechanism against CVB infection, indicating that boosting viral protein degradation may provide a new strategy for managing CVB infections.
Article Synopsis
- Group B Coxsackieviruses (CVB) can lead to myocarditis and potentially cardiomyopathy, but there's currently no effective antiviral treatment available.
- The study investigates the effects of N-acetylcysteine (NAC), an antioxidant, which was found to significantly reduce viral replication and cardiac injury caused by CVB3.
- The research reveals that NAC downregulates a specific protein, eEF1A1, that facilitates viral replication in infected cells, and promotes its degradation through autophagy, contributing to its antiviral effects.
Group B Coxsackieviruses (CVB) are non-enveloped small RNA viruses in the genus Enterovirus, family Picornaviridae. CVB infection causes diverse conditions from common cold to myocarditis, encephalitis, and pancreatitis. No specific antiviral is available for the treatment of CVB infection.
View Article and Find Full Text PDFAntiviral Activity of -Hexenoic Acid against Coxsackievirus B and Enterovirus A71.
Antimicrob Agents Chemother
March 2023
Enterovirus infections are life-threatening viral infections which occur mainly among children and are possible causes of viral outbreak. Until now, treatment and management of infections caused by members of the genus largely depended on supportive care, and no antiviral medications are currently approved for the treatment of most of these infections. The urgency of discovering new therapeutic options for the treatment of enterovirus infection is increasing.
View Article and Find Full Text PDFCoxsackievirus B (CVB), a member of genus of , is the leading pathogen of viral myocarditis and dilated cardiomyopathy. The pathogenesis of CVB-induced myocarditis has not been completely elucidated, and no specific antiviral measurement is available presently. Circular RNAs (circRNAs) have been reported to be able to modulate viral replication and infection through bridging over non-coding RNAs (ncRNAs) and coding messenger RNAs (mRNAs).
View Article and Find Full Text PDFArticle Synopsis
- Coxsackievirus group B (CVB) is linked to serious health issues like myocarditis and meningitis in younger populations, but no antiviral treatments are currently approved for it.
- Research identified ethyl 3-hydroxyhexanoate (EHX), a compound found in fruits, as a strong antiviral that can significantly block CVB replication.
- EHX has a high selective index, indicating it's effective at low concentrations without significant toxicity, and is already approved as a food additive, suggesting it could be a safe treatment option for CVB infections.
Coxsackievirus B (CVB) is the major cause of human myocarditis and dilated cardiomyopathy. Toll-like receptor 3 (TLR3) is an intracellular sensor to detect pathogen's dsRNA. TLR3, along with TRAF6, triggers an inflammatory response through NF-κB signaling pathway.
View Article and Find Full Text PDFCoxsackievirus group B (CVB) is considered as one of the most common pathogens of human viral myocarditis. CVB-induced myocarditis is mainly characterized by the persistence of the virus infection and immune-mediated inflammatory injury. Costimulatory signals are crucial for the activation of adaptive immunity.
View Article and Find Full Text PDF